Drugs / Clinolipid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04555044 | Jan 2021 → Oct 2022 | metabolic disease | Baxter Healthcare Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02476994 | May 2015 → Oct 2016 | metabolic disease | Baxter Healthcare Corporation | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-13 | Baxter Healthcare Corporation | Regulatory Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication baxter.com ↗
Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-13 | Baxter Healthcare Corporation | Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication baxter.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clinolipid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02476994 ↗ |
| Modality | Other / unclassified | “Lipid injectable emulsion, USP 20%” NCT04555044 ↗ |
| Route | Intravenous | “Study treatment will be administered intravenously” NCT04555044 ↗ |